Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $AMLX vs $ELVN | Chartloom

Compare

$AMLX vs $ELVN

Amylyx Pharmaceuticals Inc · Enliven Therapeutics Inc

AMLX

Amylyx Pharmaceuticals Inc

ELVN

Enliven Therapeutics Inc

Compare $AMLX vs $ELVN

Comparing Amylyx Pharmaceuticals Inc and Enliven Therapeutics Inc

AMLXAmylyx Pharmaceuticals Inc

ELVNEnliven Therapeutics Inc

AMLXAmylyx Pharmaceuticals Inc

Market cap

$2.99B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-100.0%

YTD performance

135.1%

52W performance

88.3%

FCF yield

-4.2%

ELVNEnliven Therapeutics Inc

Market cap

$2.76B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

154.1%

52W performance

89.7%

FCF yield

-2.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AMLX

ELVN

Detailed metrics comparison

AMLX

Amylyx Pharmaceuticals Inc

ELVN

Enliven Therapeutics Inc

Market Cap

AMLX$2.99B

ELVN$2.76B

Enterprise Value

AMLX$2.94B

ELVN$2.62B

Price

AMLX$26.85

ELVN$39.49

P/E Ratio

AMLXN/A

ELVNN/A

P/S Ratio

AMLX17.98x

ELVN0.00x

EV/Sales

AMLX17.63x

ELVN0.00x

EV/EBITDA

AMLX87.31x

ELVN770.73x

P/B Ratio

AMLX14.77x

ELVN3.35x

P/FCF Ratio

AMLXN/A

ELVNN/A

EV/FCF

AMLX-23.17x

ELVN-39.11x

PEG Ratio

AMLXN/A

ELVNN/A

Forward P/E (NTM)

AMLXN/A

ELVNN/A

Forward P/S (NTM)

AMLXN/A

ELVNN/A

Revenue (TTM)

AMLX$0

ELVN$0

Revenue Growth (YoY)

AMLX-100.0%

ELVNN/A

Forward Rev Growth

AMLX195.4%

ELVN28.4%

Gross Margin (TTM)

AMLX82.8%

ELVN0.0%

Operating Margin (TTM)

AMLX0.0%

ELVN0.0%

EBITDA Margin (TTM)

AMLX0.0%

ELVN0.0%

Net Margin (TTM)

AMLX0.0%

ELVN0.0%

FCF Margin (TTM)

AMLXN/A

ELVNN/A

Net Income (TTM)

AMLX$-152M

ELVN$-106M

FCF (TTM)

AMLX$-127M

ELVN$-67M

EPS (TTM)

AMLX-$1.37

ELVN-$1.60

ROE (TTM)

AMLX-5292.0%

ELVN-1855.0%

ROA (TTM)

AMLX-4853.0%

ELVN-1809.0%

ROIC (TTM)

AMLX-5292.0%

ELVN-1855.0%

Cash

AMLX$49M

ELVN$136M

Debt

AMLX$0

ELVN$0

Net Cash/Debt

AMLX$49M

ELVN$136M

Current Ratio (TTM)

AMLX12.12x

ELVN64.07x

Quick Ratio (TTM)

AMLX11.86x

ELVN63.21x

Debt/Equity (TTM)

AMLX0.00x

ELVN0.00x

Debt/Assets (TTM)

AMLX0.0%

ELVN0.0%

Interest Coverage (TTM)

AMLXN/A

ELVNN/A

Net Debt/EBITDA (TTM)

AMLX0.00x

ELVN0.00x

Beta

AMLX-0.10

ELVN0.55

52W Performance

AMLX88.3%

ELVN89.7%

YTD Performance

AMLX135.1%

ELVN154.1%

% from 52W High

AMLX-34.7%

ELVN-36.6%

% from 52W Low

AMLX147.9%

ELVN167.1%

Asset Turnover (TTM)

AMLX0.50x

ELVN0.00x

FCF Yield (TTM)

AMLX-4.2%

ELVN-2.4%

Earnings Yield (TTM)

AMLX-5.1%

ELVN-3.8%

Dividend Yield (TTM)

AMLXN/A

ELVNN/A

Rule of 40

AMLX-100.0

ELVN0.0

EV/GP/RG

AMLXN/A

ELVNN/A

Ticker research

View AMLX research View ELVN research

Metric	AMLX Amylyx Pharmaceuticals Inc	ELVN Enliven Therapeutics Inc
Market & Valuation
Market Cap	$2.99B	$2.76B
Enterprise Value	$2.94B	$2.62B
Price	$26.85	$39.49
P/E Ratio	N/A	N/A
P/S Ratio	17.98x	0.00x
EV/Sales	17.63x	0.00x
EV/EBITDA	87.31x	770.73x
P/B Ratio	14.77x	3.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-23.17x	-39.11x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	-100.0%	N/A
Forward Rev Growth	195.4%	28.4%
Profitability
Gross Margin (TTM)	82.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-152M	$-106M
FCF (TTM)	$-127M	$-67M
EPS (TTM)	-$1.37	-$1.60
ROE (TTM)	-5292.0%	-1855.0%
ROA (TTM)	-4853.0%	-1809.0%
ROIC (TTM)	-5292.0%	-1855.0%
Financial Health
Cash	$49M	$136M
Debt	$0	$0
Net Cash/Debt	$49M	$136M
Current Ratio (TTM)	12.12x	64.07x
Quick Ratio (TTM)	11.86x	63.21x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.10	0.55
52W Performance	88.3%	89.7%
YTD Performance	135.1%	154.1%
% from 52W High	-34.7%	-36.6%
% from 52W Low	147.9%	167.1%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	0.00x
FCF Yield (TTM)	-4.2%	-2.4%
Earnings Yield (TTM)	-5.1%	-3.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View AMLX research	View ELVN research

Valuation

P/S Ratio

ELVN

0.00x

AMLX

17.98x

EV/FCF

ELVN

-39.11x

AMLX

-23.17x

Growth & revenue

Revenue Growth TTM

AMLX

-100.0%

Forward Revenue Growth

AMLX

195.4%

ELVN

28.4%

Profitability & performance

Gross Margin

AMLX

82.8%

ELVN

0.0%

ROE

ELVN

-1855.0%

AMLX

-5292.0%

FCF Yield %

ELVN

-2.4%

AMLX

-4.2%

52-Week Performance

ELVN

89.7%

AMLX

88.3%

Detailed metrics comparison

AMLX

Amylyx Pharmaceuticals Inc

ELVN

Enliven Therapeutics Inc

Market Cap

AMLX$2.99B

ELVN$2.76B

Enterprise Value

AMLX$2.94B

ELVN$2.62B

Price

AMLX$26.85

ELVN$39.49

P/E Ratio

AMLXN/A

ELVNN/A

P/S Ratio

AMLX17.98x

ELVN0.00x

EV/Sales

AMLX17.63x

ELVN0.00x

EV/EBITDA

AMLX87.31x

ELVN770.73x

P/B Ratio

AMLX14.77x

ELVN3.35x

P/FCF Ratio

AMLXN/A

ELVNN/A

EV/FCF

AMLX-23.17x

ELVN-39.11x

PEG Ratio

AMLXN/A

ELVNN/A

Forward P/E (NTM)

AMLXN/A

ELVNN/A

Forward P/S (NTM)

AMLXN/A

ELVNN/A

Revenue (TTM)

AMLX$0

ELVN$0

Revenue Growth (YoY)

AMLX-100.0%

ELVNN/A

Forward Rev Growth

AMLX195.4%

ELVN28.4%

Gross Margin (TTM)

AMLX82.8%

ELVN0.0%

Operating Margin (TTM)

AMLX0.0%

ELVN0.0%

EBITDA Margin (TTM)

AMLX0.0%

ELVN0.0%

Net Margin (TTM)

AMLX0.0%

ELVN0.0%

FCF Margin (TTM)

AMLXN/A

ELVNN/A

Net Income (TTM)

AMLX$-152M

ELVN$-106M

FCF (TTM)

AMLX$-127M

ELVN$-67M

EPS (TTM)

AMLX-$1.37

ELVN-$1.60

ROE (TTM)

AMLX-5292.0%

ELVN-1855.0%

ROA (TTM)

AMLX-4853.0%

ELVN-1809.0%

ROIC (TTM)

AMLX-5292.0%

ELVN-1855.0%

Cash

AMLX$49M

ELVN$136M

Debt

AMLX$0

ELVN$0

Net Cash/Debt

AMLX$49M

ELVN$136M

Current Ratio (TTM)

AMLX12.12x

ELVN64.07x

Quick Ratio (TTM)

AMLX11.86x

ELVN63.21x

Debt/Equity (TTM)

AMLX0.00x

ELVN0.00x

Debt/Assets (TTM)

AMLX0.0%

ELVN0.0%

Interest Coverage (TTM)

AMLXN/A

ELVNN/A

Net Debt/EBITDA (TTM)

AMLX0.00x

ELVN0.00x

Beta

AMLX-0.10

ELVN0.55

52W Performance

AMLX88.3%

ELVN89.7%

YTD Performance

AMLX135.1%

ELVN154.1%

% from 52W High

AMLX-34.7%

ELVN-36.6%

% from 52W Low

AMLX147.9%

ELVN167.1%

Asset Turnover (TTM)

AMLX0.50x

ELVN0.00x

FCF Yield (TTM)

AMLX-4.2%

ELVN-2.4%

Earnings Yield (TTM)

AMLX-5.1%

ELVN-3.8%

Dividend Yield (TTM)

AMLXN/A

ELVNN/A

Rule of 40

AMLX-100.0

ELVN0.0

EV/GP/RG

AMLXN/A

ELVNN/A

Ticker research

View AMLX research View ELVN research

Metric	AMLX Amylyx Pharmaceuticals Inc	ELVN Enliven Therapeutics Inc
Market & Valuation
Market Cap	$2.99B	$2.76B
Enterprise Value	$2.94B	$2.62B
Price	$26.85	$39.49
P/E Ratio	N/A	N/A
P/S Ratio	17.98x	0.00x
EV/Sales	17.63x	0.00x
EV/EBITDA	87.31x	770.73x
P/B Ratio	14.77x	3.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-23.17x	-39.11x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	-100.0%	N/A
Forward Rev Growth	195.4%	28.4%
Profitability
Gross Margin (TTM)	82.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-152M	$-106M
FCF (TTM)	$-127M	$-67M
EPS (TTM)	-$1.37	-$1.60
ROE (TTM)	-5292.0%	-1855.0%
ROA (TTM)	-4853.0%	-1809.0%
ROIC (TTM)	-5292.0%	-1855.0%
Financial Health
Cash	$49M	$136M
Debt	$0	$0
Net Cash/Debt	$49M	$136M
Current Ratio (TTM)	12.12x	64.07x
Quick Ratio (TTM)	11.86x	63.21x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.10	0.55
52W Performance	88.3%	89.7%
YTD Performance	135.1%	154.1%
% from 52W High	-34.7%	-36.6%
% from 52W Low	147.9%	167.1%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	0.00x
FCF Yield (TTM)	-4.2%	-2.4%
Earnings Yield (TTM)	-5.1%	-3.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View AMLX research	View ELVN research